laronidase Search Results


  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 95
    Genzyme laronidase
    <t>Anti-laronidase</t> Antibodies in MPS I Mice Treated with Immune Tolerance Induction Regimens (A) All MPS I mice from the treatment group (n = 8) received 0.58 mg/kg laronidase for 10 weeks. Laronidase delivered on day 49 was delivered in Sigma Adjuvant System (SAS). Immune tolerance induction (ITI) regimens were delivered to the mice (methotrexate, anti-CD4 and anti-CD8 monoclonal antibodies, and methotrexate with both monoclonal antibodies) 0, 24, and 48 h after the first laronidase treatment. Serum samples were taken on days 0, 28, and 70 for antibody analysis. Mice were sacrificed on day 70. (B) Anti-laronidase IgG antibody levels were measured in all serum samples using ELISA. Data are shown as mean ± SEM, two-way ANOVA; *p
    Laronidase, supplied by Genzyme, used in various techniques. Bioz Stars score: 95/100, based on 40 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/laronidase/product/Genzyme
    Average 95 stars, based on 40 article reviews
    Price from $9.99 to $1999.99
    laronidase - by Bioz Stars, 2020-04
    95/100 stars
      Buy from Supplier

    86
    Genzyme aldurazyme laronidase
    <t>Anti-laronidase</t> Antibodies in MPS I Mice Treated with Immune Tolerance Induction Regimens (A) All MPS I mice from the treatment group (n = 8) received 0.58 mg/kg laronidase for 10 weeks. Laronidase delivered on day 49 was delivered in Sigma Adjuvant System (SAS). Immune tolerance induction (ITI) regimens were delivered to the mice (methotrexate, anti-CD4 and anti-CD8 monoclonal antibodies, and methotrexate with both monoclonal antibodies) 0, 24, and 48 h after the first laronidase treatment. Serum samples were taken on days 0, 28, and 70 for antibody analysis. Mice were sacrificed on day 70. (B) Anti-laronidase IgG antibody levels were measured in all serum samples using ELISA. Data are shown as mean ± SEM, two-way ANOVA; *p
    Aldurazyme Laronidase, supplied by Genzyme, used in various techniques. Bioz Stars score: 86/100, based on 3 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/aldurazyme laronidase/product/Genzyme
    Average 86 stars, based on 3 article reviews
    Price from $9.99 to $1999.99
    aldurazyme laronidase - by Bioz Stars, 2020-04
    86/100 stars
      Buy from Supplier

    92
    BioMarin laronidase
    Distribution of treatment modalities over time. Data represent all patients enrolled in the Registry as of March 2010 who report treatment with either HSCT, <t>laronidase,</t> or both. An additional 116 patients reported no treatment
    Laronidase, supplied by BioMarin, used in various techniques. Bioz Stars score: 92/100, based on 17 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/laronidase/product/BioMarin
    Average 92 stars, based on 17 article reviews
    Price from $9.99 to $1999.99
    laronidase - by Bioz Stars, 2020-04
    92/100 stars
      Buy from Supplier

    84
    Genzyme recombinant idua laronidase
    Distribution of treatment modalities over time. Data represent all patients enrolled in the Registry as of March 2010 who report treatment with either HSCT, <t>laronidase,</t> or both. An additional 116 patients reported no treatment
    Recombinant Idua Laronidase, supplied by Genzyme, used in various techniques. Bioz Stars score: 84/100, based on 2 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/recombinant idua laronidase/product/Genzyme
    Average 84 stars, based on 2 article reviews
    Price from $9.99 to $1999.99
    recombinant idua laronidase - by Bioz Stars, 2020-04
    84/100 stars
      Buy from Supplier

    80
    Sanofi recombinant human α l iduronidase laronidase
    Distribution of treatment modalities over time. Data represent all patients enrolled in the Registry as of March 2010 who report treatment with either HSCT, <t>laronidase,</t> or both. An additional 116 patients reported no treatment
    Recombinant Human α L Iduronidase Laronidase, supplied by Sanofi, used in various techniques. Bioz Stars score: 80/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/recombinant human α l iduronidase laronidase/product/Sanofi
    Average 80 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    recombinant human α l iduronidase laronidase - by Bioz Stars, 2020-04
    80/100 stars
      Buy from Supplier

    85
    Covance polyclonal rabbit anti laronidase
    Distribution of treatment modalities over time. Data represent all patients enrolled in the Registry as of March 2010 who report treatment with either HSCT, <t>laronidase,</t> or both. An additional 116 patients reported no treatment
    Polyclonal Rabbit Anti Laronidase, supplied by Covance, used in various techniques. Bioz Stars score: 85/100, based on 6 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/polyclonal rabbit anti laronidase/product/Covance
    Average 85 stars, based on 6 article reviews
    Price from $9.99 to $1999.99
    polyclonal rabbit anti laronidase - by Bioz Stars, 2020-04
    85/100 stars
      Buy from Supplier

    Image Search Results


    Anti-laronidase Antibodies in MPS I Mice Treated with Immune Tolerance Induction Regimens (A) All MPS I mice from the treatment group (n = 8) received 0.58 mg/kg laronidase for 10 weeks. Laronidase delivered on day 49 was delivered in Sigma Adjuvant System (SAS). Immune tolerance induction (ITI) regimens were delivered to the mice (methotrexate, anti-CD4 and anti-CD8 monoclonal antibodies, and methotrexate with both monoclonal antibodies) 0, 24, and 48 h after the first laronidase treatment. Serum samples were taken on days 0, 28, and 70 for antibody analysis. Mice were sacrificed on day 70. (B) Anti-laronidase IgG antibody levels were measured in all serum samples using ELISA. Data are shown as mean ± SEM, two-way ANOVA; *p

    Journal: Molecular Therapy. Methods & Clinical Development

    Article Title: Strategies for the Induction of Immune Tolerance to Enzyme Replacement Therapy in Mucopolysaccharidosis Type I

    doi: 10.1016/j.omtm.2019.02.007

    Figure Lengend Snippet: Anti-laronidase Antibodies in MPS I Mice Treated with Immune Tolerance Induction Regimens (A) All MPS I mice from the treatment group (n = 8) received 0.58 mg/kg laronidase for 10 weeks. Laronidase delivered on day 49 was delivered in Sigma Adjuvant System (SAS). Immune tolerance induction (ITI) regimens were delivered to the mice (methotrexate, anti-CD4 and anti-CD8 monoclonal antibodies, and methotrexate with both monoclonal antibodies) 0, 24, and 48 h after the first laronidase treatment. Serum samples were taken on days 0, 28, and 70 for antibody analysis. Mice were sacrificed on day 70. (B) Anti-laronidase IgG antibody levels were measured in all serum samples using ELISA. Data are shown as mean ± SEM, two-way ANOVA; *p

    Article Snippet: Briefly, 96-well enzyme immunoassay (EIA) plates were coated with 5 μg/mL laronidase (recombinant α-iduronidase; Genzyme, Cambridge, MA) diluted in coating buffer (1 M NaHCO3 [pH 8.5]) overnight and blocked with blocking buffer containing 1% human serum albumin.

    Techniques: Mouse Assay, Enzyme-linked Immunosorbent Assay

    Anti-laronidase IgG Antibodies in MPS I Mice Treated with Either Anti-CD4 or Anti-CD8 Monoclonal Antibody (A) All MPS I mice from the treatment group (n = 8) received 0.58 mg/kg laronidase for 10 weeks. Laronidase delivered on day 49 was delivered in adjuvant. They were given either anti-CD4 monoclonal antibody or anti-CD8 monoclonal antibody at 0, 24, and 48 h after the first laronidase treatment and at 0, 24, and 48 h after the adjuvant stimulation. Serum samples were taken on days 0, 28, 42, and 70 for antibody analysis. Mice were sacrificed on day 70. (B) Anti-laronidase IgG antibody levels were measured in all serum samples using ELISA. Data are shown as mean ± SEM, two-way ANOVA; *p

    Journal: Molecular Therapy. Methods & Clinical Development

    Article Title: Strategies for the Induction of Immune Tolerance to Enzyme Replacement Therapy in Mucopolysaccharidosis Type I

    doi: 10.1016/j.omtm.2019.02.007

    Figure Lengend Snippet: Anti-laronidase IgG Antibodies in MPS I Mice Treated with Either Anti-CD4 or Anti-CD8 Monoclonal Antibody (A) All MPS I mice from the treatment group (n = 8) received 0.58 mg/kg laronidase for 10 weeks. Laronidase delivered on day 49 was delivered in adjuvant. They were given either anti-CD4 monoclonal antibody or anti-CD8 monoclonal antibody at 0, 24, and 48 h after the first laronidase treatment and at 0, 24, and 48 h after the adjuvant stimulation. Serum samples were taken on days 0, 28, 42, and 70 for antibody analysis. Mice were sacrificed on day 70. (B) Anti-laronidase IgG antibody levels were measured in all serum samples using ELISA. Data are shown as mean ± SEM, two-way ANOVA; *p

    Article Snippet: Briefly, 96-well enzyme immunoassay (EIA) plates were coated with 5 μg/mL laronidase (recombinant α-iduronidase; Genzyme, Cambridge, MA) diluted in coating buffer (1 M NaHCO3 [pH 8.5]) overnight and blocked with blocking buffer containing 1% human serum albumin.

    Techniques: Mouse Assay, Enzyme-linked Immunosorbent Assay

    Biomarker Responses to Laronidase in MPS I Hurler Patients Receiving Immune Tolerance Induction with Methotrexate (A) Total urinary glycosaminoglycan in all patients. (B) Heparan sulfate and dermatan sulfate concentrations in urine in all patients. (C) Heparan sulfate and dermatan sulfate concentrations in serum in all patients. (D) Treg population in patient PBMCs, expressed as the percentage of CD4 + T cells. Individual data points are shown; *p

    Journal: Molecular Therapy. Methods & Clinical Development

    Article Title: Strategies for the Induction of Immune Tolerance to Enzyme Replacement Therapy in Mucopolysaccharidosis Type I

    doi: 10.1016/j.omtm.2019.02.007

    Figure Lengend Snippet: Biomarker Responses to Laronidase in MPS I Hurler Patients Receiving Immune Tolerance Induction with Methotrexate (A) Total urinary glycosaminoglycan in all patients. (B) Heparan sulfate and dermatan sulfate concentrations in urine in all patients. (C) Heparan sulfate and dermatan sulfate concentrations in serum in all patients. (D) Treg population in patient PBMCs, expressed as the percentage of CD4 + T cells. Individual data points are shown; *p

    Article Snippet: Briefly, 96-well enzyme immunoassay (EIA) plates were coated with 5 μg/mL laronidase (recombinant α-iduronidase; Genzyme, Cambridge, MA) diluted in coating buffer (1 M NaHCO3 [pH 8.5]) overnight and blocked with blocking buffer containing 1% human serum albumin.

    Techniques: Biomarker Assay

    Methotrexate Dose Optimization Delivery Schedule and Antibody Levels in MPS I Mice (A) All MPS I mice (n = 3 for each group) received 0.58 mg/kg laronidase weekly for 4 weeks. Some mice were given three cycles of 0.5 mg/kg methotrexate 0, 24, and 48 h after each laronidase treatment, and other mice received one cycle of methotrexate (doses ranged from 0.5 to 16 mg/kg) 0, 24, and 48 h after the first laronidase treatment. Blood samples were taken from all the mice on days 0, 13, and 28 for antibody analysis. (B) Serum anti-laronidase IgG antibodies were evaluated by ELISA. Data are shown as mean ± SEM, two-way ANOVA; *p

    Journal: Molecular Therapy. Methods & Clinical Development

    Article Title: Strategies for the Induction of Immune Tolerance to Enzyme Replacement Therapy in Mucopolysaccharidosis Type I

    doi: 10.1016/j.omtm.2019.02.007

    Figure Lengend Snippet: Methotrexate Dose Optimization Delivery Schedule and Antibody Levels in MPS I Mice (A) All MPS I mice (n = 3 for each group) received 0.58 mg/kg laronidase weekly for 4 weeks. Some mice were given three cycles of 0.5 mg/kg methotrexate 0, 24, and 48 h after each laronidase treatment, and other mice received one cycle of methotrexate (doses ranged from 0.5 to 16 mg/kg) 0, 24, and 48 h after the first laronidase treatment. Blood samples were taken from all the mice on days 0, 13, and 28 for antibody analysis. (B) Serum anti-laronidase IgG antibodies were evaluated by ELISA. Data are shown as mean ± SEM, two-way ANOVA; *p

    Article Snippet: Briefly, 96-well enzyme immunoassay (EIA) plates were coated with 5 μg/mL laronidase (recombinant α-iduronidase; Genzyme, Cambridge, MA) diluted in coating buffer (1 M NaHCO3 [pH 8.5]) overnight and blocked with blocking buffer containing 1% human serum albumin.

    Techniques: Mouse Assay, Enzyme-linked Immunosorbent Assay

    Immune Tolerance Induction with Methotrexate in Hurler Syndrome Study Schedule and Antibody Responses to Laronidase in MPS I Hurler Patients (A) Immune tolerance induction with methotrexate in Hurler syndrome study schedule. The first two participants were allocated to regimen 1 (1 cycle of methotrexate). A subsequent participant was allocated to regimen 2 (3 cycles of methotrexate). Each cycle comprised three doses of 0.4 mg/kg methotrexate administered orally around an infusion of laronidase (60 min prior to infusion, 24 h after infusion, and 48 h after infusion). (B) All participants developed high titers of IgG to laronidase despite the methotrexate regimen. An antibody response was evident by week 4, and a relative reduction in antibody titers was evident post-HSCT. (C) Peak anti-laronidase IgG titers were comparable to those seen in a historical longitudinal study 11 of antibody responses to laronidase. (D) An IgM response was evident by week 4 in all participants, including subject 3 who received methotrexate for 3 cycles (week 4 time point was

    Journal: Molecular Therapy. Methods & Clinical Development

    Article Title: Strategies for the Induction of Immune Tolerance to Enzyme Replacement Therapy in Mucopolysaccharidosis Type I

    doi: 10.1016/j.omtm.2019.02.007

    Figure Lengend Snippet: Immune Tolerance Induction with Methotrexate in Hurler Syndrome Study Schedule and Antibody Responses to Laronidase in MPS I Hurler Patients (A) Immune tolerance induction with methotrexate in Hurler syndrome study schedule. The first two participants were allocated to regimen 1 (1 cycle of methotrexate). A subsequent participant was allocated to regimen 2 (3 cycles of methotrexate). Each cycle comprised three doses of 0.4 mg/kg methotrexate administered orally around an infusion of laronidase (60 min prior to infusion, 24 h after infusion, and 48 h after infusion). (B) All participants developed high titers of IgG to laronidase despite the methotrexate regimen. An antibody response was evident by week 4, and a relative reduction in antibody titers was evident post-HSCT. (C) Peak anti-laronidase IgG titers were comparable to those seen in a historical longitudinal study 11 of antibody responses to laronidase. (D) An IgM response was evident by week 4 in all participants, including subject 3 who received methotrexate for 3 cycles (week 4 time point was

    Article Snippet: Briefly, 96-well enzyme immunoassay (EIA) plates were coated with 5 μg/mL laronidase (recombinant α-iduronidase; Genzyme, Cambridge, MA) diluted in coating buffer (1 M NaHCO3 [pH 8.5]) overnight and blocked with blocking buffer containing 1% human serum albumin.

    Techniques:

    Cellular Uptake Inhibition and CD4 + Cell Counts (A) Cellular uptake inhibition of laronidase was measured in serum samples taken at endpoint (day 70) from all treated mice. Dotted line represents clinically relevant cellular uptake inhibition percentage ( > 30%). Data are shown as mean ± SEM, one-way ANOVA; *p

    Journal: Molecular Therapy. Methods & Clinical Development

    Article Title: Strategies for the Induction of Immune Tolerance to Enzyme Replacement Therapy in Mucopolysaccharidosis Type I

    doi: 10.1016/j.omtm.2019.02.007

    Figure Lengend Snippet: Cellular Uptake Inhibition and CD4 + Cell Counts (A) Cellular uptake inhibition of laronidase was measured in serum samples taken at endpoint (day 70) from all treated mice. Dotted line represents clinically relevant cellular uptake inhibition percentage ( > 30%). Data are shown as mean ± SEM, one-way ANOVA; *p

    Article Snippet: Briefly, 96-well enzyme immunoassay (EIA) plates were coated with 5 μg/mL laronidase (recombinant α-iduronidase; Genzyme, Cambridge, MA) diluted in coating buffer (1 M NaHCO3 [pH 8.5]) overnight and blocked with blocking buffer containing 1% human serum albumin.

    Techniques: Inhibition, Mouse Assay

    Distribution of treatment modalities over time. Data represent all patients enrolled in the Registry as of March 2010 who report treatment with either HSCT, laronidase, or both. An additional 116 patients reported no treatment

    Journal: European Journal of Pediatrics

    Article Title: Diagnosis and treatment trends in mucopolysaccharidosis I: findings from the MPS I Registry

    doi: 10.1007/s00431-011-1644-x

    Figure Lengend Snippet: Distribution of treatment modalities over time. Data represent all patients enrolled in the Registry as of March 2010 who report treatment with either HSCT, laronidase, or both. An additional 116 patients reported no treatment

    Article Snippet: Enzyme replacement therapy (ERT) with laronidase (recombinant human α-l -iduronidase; Aldurazyme®, BioMarin Pharmaceutical and Genzyme, a Sanofi Company) was approved in 2003 to treat the non-neurologic manifestations of MPS I and is the primary treatment option for patients with Hurler–Scheie and Scheie syndromes.

    Techniques:

    Use of laronidase with HSCT by year of first treatment. First treatment is defined as either HSCT or laronidase, whichever occurred first. For all treatment periods, 92% of Registry patients who received both HSCT and laronidase received laronidase during the peri-transplant period, defined as any time during the interval 6 months before and 3 months after HSCT. All data are as of March 2010

    Journal: European Journal of Pediatrics

    Article Title: Diagnosis and treatment trends in mucopolysaccharidosis I: findings from the MPS I Registry

    doi: 10.1007/s00431-011-1644-x

    Figure Lengend Snippet: Use of laronidase with HSCT by year of first treatment. First treatment is defined as either HSCT or laronidase, whichever occurred first. For all treatment periods, 92% of Registry patients who received both HSCT and laronidase received laronidase during the peri-transplant period, defined as any time during the interval 6 months before and 3 months after HSCT. All data are as of March 2010

    Article Snippet: Enzyme replacement therapy (ERT) with laronidase (recombinant human α-l -iduronidase; Aldurazyme®, BioMarin Pharmaceutical and Genzyme, a Sanofi Company) was approved in 2003 to treat the non-neurologic manifestations of MPS I and is the primary treatment option for patients with Hurler–Scheie and Scheie syndromes.

    Techniques: